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Alzheimer’s disease (AD) is a neurodegenerative disorder
deﬁnedbyprogressivememorylossandcognitiveimpairment
and at the molecular level by the presence of neuroﬁbrillary
tangles (NFTs) and insoluble b-amyloid (Ab) plaques (Hardy
2006) that are associated with activated microglia (Vehmas
et al. 2003). NFTs are composed of hyper-phosphorylated
forms of the microtubule-associated protein tau, whereas Ab
is derived from the proteolytic cleavage of b-amyloid
precursor protein (APP). Early onset forms of Familial
Alzheimer’s disease (FAD) typically present before the age
of 65 and have been linked to mutations in APP, presenilin-1
(PS-1) and presenilin-2 (PS-2). Mutations in these genes
adversely affect APP processing and result in the increased
production of insoluble Ab and its deposition into plaques.
b-Amyloid precursor protein, presenilin and tau are
undoubtedly pivotal to understanding the pathogenesis of
AD and there are as yet no convincing refutations of
the classical amyloid cascade hypothesis of AD, which
postulates that, Ab over-production leads to the pathogenic
hyper-phosphorylation of tau resulting in the formation of
neuroﬁbrillary tangles (NFTs) and neurodegeneration. How-
ever, this hypothesis raises as many questions as it does
answers.WhatregulatestheprocessingofAPPinsporadicAD
as opposed to those very few families harboring APP or PS
mutations? Which species of Ab (Ab42, Ab*56, aggregated
ﬁbrillar Ab or soluble oligomeric Ab, intracellular Ab or
extracellular Ab) is neurotoxic and how exactly does Ab
induce tau hyper-phosphorylation and does this lead to tau
aggregation, neurotoxicity and loss of neuronal function?
Thesearenotidlequestions,drugdevelopmentintheADﬁeld
has concentrated very heavily on trying to alter APP process-
ing, but developing alternative approaches is almost certainly
going to be necessary for the effective treatment of this
devastating and costly condition. We propose that glycogen
synthasekinase-3(GSK3)playsaleadingroleinthecascadeof
events that culminate in AD as this kinase is involved in the
mechanisms underlying learning and memory, in the hyper-
phosphorylationoftau,intheincreasedproductionofAbfrom
APP and also in local cerebral inﬂammatory responses.
GSK3 and cell signaling
TherearetwoGSK3genesfromwhichGSK3aandGSK3bare
derived. GSK3b also exists as longer splice variants (Mukai
et al. 2002; Schaffer et al. 2003). GSK3a and GSK3b are
ubiquitously expressed, constitutively active, proline-directed
serine/threonine kinases involved in a variety of cellular
processes including glycogen metabolism (Welsh and Proud
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Abstract
Glycogen synthase kinase 3 (GSK3) is a constitutively active,
proline-directed serine/threonine kinase that plays a part in a
number of physiological processes ranging from glycogen
metabolism to gene transcription. GSK3 also plays a pivotal
and central role in the pathogenesis of both sporadic and
familial forms of Alzheimer’s disease (AD), an observation that
has led us to coin the ‘GSK3 hypothesis of AD’. According to
this hypothesis, over-activity of GSK3 accounts for memory
impairment, tau hyper-phosphorylation, increased b-amyloid
production and local plaque-associated microglial-mediated
inﬂammatory responses; all of which are hallmark character-
istics of AD. If our ‘GSK3 hypothesis of AD’ is substantiated
and GSK3 is indeed a causal mediator of AD then inhibitors of
GSK3 would provide a novel avenue for therapeutic inter-
vention in this devastating disorder.
Keywords: Wnt, insulin, tau, b-amyloid, memory, inﬂamma-
tion.
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(Turenne and Price 2001) and microtubule stability (Anderton
et al. 2001; Brion et al. 2001). Insights from mouse models
suggest that the GSK3 isoforms exhibit tissue speciﬁc
physiological functions. GSK3b knock-out mice die in utero
(Hoeﬂich et al. 2000), whereas GSK3a knock-out mice are
viable and display improved glucose tolerance in response to
glucoseloadandelevatedhepaticglycogenstorageandinsulin
sensitivity (MacAulay et al. 2007).
GSK3 activity is modulated by insulin and Wnt signaling,
both pathways act in a negative regulatory manner. Many, but
notallGSK3substratesrequirepre-phosphorylation(priming)
before phosphorylation by GSK3 can occur, so in both health
anddiseasetheactivityoftheprimingkinasemightlimitGSK3
activity. Insulin signaling leads to the activation of PI3-kinase
and subsequently the activation of acutely transforming
retrovirus Akt8 in rodent T cell lymphoma (Akt otherwise
known as protein kinase B), which in turn phosphorylates free
cytoplasmic GSK3b and GSK3a at serine (Ser) residues 9 and
21, respectively (Saltiel and Kahn 2001; Lizcano and Alessi
2002). Regulatory serine phosphorylation results in the
generation of an intra-molecular pseudo-substrate, which
blocks part of the active site preventing the enzymatic activity
of GSK3 towards primed substrates. This in turn leads to
the de-phosphorylation of downstream substrates such as
glycogen synthase and eukaryotic protein synthesis initiation
factor-2B (eIF-2B), which elicits an increase in glycogen and
proteinsynthesis.GSK3canalsobephosphorylatedatSer9/21
by p70 ribosomal S6 kinase-1 (S6K1) and by 90 kDa
ribosomal protein S6 kinase (RSK), a downstream mediator
ofmitogen-activatedproteinkinase(MAPK)signaling(Doble
and Woodgett 2003).
In addition to regulatory Ser phosphorylation, GSK3b and
GSK3a activity can be regulated by tyrosine (Tyr) phos-
phorylation at residues 216 or 279, respectively. Under
physiological conditions, GSK3 is phosphorylated at these
sites and increases in Tyr phosphorylation augment GSK3
activity. However, regulation of GSK3 at Tyr 216/279 is
perhaps less common than regulation at Ser9/21 (Bhat et al.
2000; Bijur and Jope 2001).
Wnt signaling regulates GSK3 activity by physically
displacing complexed GSK3 from a number of regulatory
binding partners consequently preventing the phosphoryla-
tion and degradation of b-catenin. In the absence of Wnt, the
signaling pool of b-catenin is maintained at low levels
through degradation (Dale 1998; Huelsken and Behrens
2002; Nusse 2005). b-catenin is targeted for ubiquitination
by the b-transducin repeat containing protein (bTrCP) and is
then degraded by the proteosome. b-catenin is phosphory-
lated by the serine/threonine kinases casein kinase 1 (CK1)
and GSK3b. Phosphorylation of b-catenin occurs in a multi-
protein complex (the destruction complex), comprising axin,
adenomatous polyposis coli protein and diversin. Upon
receipt of a Wnt signal, dishevelled prevents degradation of
b-catenin through the recruitment of GSK3 binding protein
(GBP)/Frat-1, which displaces GSK3b from the destruction
complex. Stabilized b-catenin enters the nucleus and asso-
ciates with T cell factor/lymphoid enhancer factor transcrip-
tion factors, leading to the transcription of Wnt target genes,
such as cyclin D1, PPARd and twin. Recently, GSK3a in
addition to GSK3b, has been shown to function in the
destruction complex and the Wnt signaling pathway, sug-
gesting that this enzyme is equally as important in Wnt
biology as is GSK3b (Asuni et al. 2006; Doble et al. 2007).
The role of GSK3 in AD
The evidence that GSK3 plays a central role in AD and that its
deregulation accounts for many of the pathological hallmarks
of the disease in both sporadic and familial AD cases, has led
us to formulate the ‘GSK3 hypothesis of AD.’ Evidence from
our group and others suggests that GSK3 is intimately
involved in the hyper-phosphorylation of tau, memory
impairment, the increased production of Ab and in inﬂam-
matory responses (Fig. 1). GSK3 also reduces acetylcholine
synthesis, which is in accordance with the cholinergic deﬁcit
present in AD (Hoshi et al. 1996). Moreover, GSK3 is a key
mediator of apoptosis (Turenne and Price 2001) and thereby
might directly contribute to neuronal loss in AD.
Indeed, if GSK3 is central to AD pathogenesis then one
wouldexpect evidencefor increased activityof this enzymein
AD. However, there is little such evidence, as it is technically
difﬁcult, if not impossible, to measure enzymatic activity in
post-mortembraintissue.Nevertheless,indirectevidencedoes
support the role of GSK3 in disease. GSK3 has been shown to
co-localize with dystrophic neurites and NFTs (Yamaguchi
et al.1996;ImahoriandUchida1997;Peiet al.1997).Active
GSK3 appears in neurons with pre-tangle changes (Pei et al.
1999)andthereisincreasedGSK3activityinthefrontalcortex
in AD as evidenced by immuno-blotting for GSK3 phosphor-
ylated at Tyr216 (Leroy et al. 2007). Furthermore, GSK3
expression is up-regulated in the hippocampus of AD patients
(Blalock et al. 2004) and in post-synaptosomal supernatants
derived from AD brain (Pei et al. 1997), although the latter
study reports that there is not an increase in GSK3 enzymatic
activity. GSK3 expression is also up-regulated in circulating
peripheral lymphocytes in both AD and in mild cognitive
impairment (Hye et al. 2005). It has recently been reported
that a polymorphism in the GSK3 promoter is a risk factor for
late onset AD (Mateo et al. 2006), which might account for
alterations in GSK3 expression in disease. Collectively, these
ﬁndingssuggestthat GSK3activity mightbe increasedinAD,
through changes in its phosphorylation state as well as
expression levels, although we acknowledge that direct
evidence for this is still limited at present and some studies
ﬁnd no change in GSK3 activity (Pei et al. 1997) or reduced
GSK3 activity (Swatton et al. 2004) in AD.
Genetic and epidemiological studies indicate that GSK3 is
deregulated in AD through alterations in upstream Wnt and
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lipoprotein receptor related Protein 6 (LRP6), a co-receptor
for Wnt signaling, has recently been identiﬁed as a risk gene
for late onset AD in apolipoprotein E4-e4 negative individ-
uals (De Ferrari et al. 2007), implicating aberrant Wnt
signalling in AD pathology. In addition, an association of AD
with diabetes and insulin resistance has been reported
(Biessels and Kappelle 2005) and genetic studies ﬁnd insulin
signaling genes to be susceptibility loci for AD (Hamilton
et al. 2007; Reiman et al. 2007).
GSK3 and memory
Suppression of Wnt or PI3-kinase signaling impairs long
term potentiation (LTP), the best characterized correlate of
learning and memory (Sanna et al. 2002; Chen et al. 2006).
GSK3 is negatively regulated by both the Wnt and insulin
pathways and inhibition of GSK3b follows the induction of
LTP in wild-type mice (Hooper et al. 2007; Peineau et al.
2007) suggesting that GSK3b might mediate the effects of
insulin and Wnt on LTP. Accordingly, over-expression of
GSK3b in mice prevents the induction of LTP (Hooper
et al. 2007) and causes a decrease in spatial learning
(Hernandez et al. 2002). Inhibitors of GSK3b have also
been shown to block long-term depression (LTD) and
GSK3b activity is enhanced during LTD (Peineau et al.
2007). Thus, it would appear that GSK3b is critical for the
induction of memory formation, switching off LTD and
allowing LTP to occur.
Many downstream substrates of GSK3 are involved in
synaptic remodeling, which is a vital process required for
the proper establishment of connections during memory
formation. Adenomatous polyposis coli a synaptic scaffold-
ing protein (Rubinfeld et al. 1996) and collapsin response
mediator proteins (CRMPs) are known to inﬂuence growth
cone dynamics and are hyper-phosphorylated in Ab plaques
(Cole et al. 2004). GSK3 also phosphorylates and inhibits
cAMP responsive element-binding protein (Bullock and
Habener 1998; Hansen et al. 2004), a universal modulator of
memory. Moreover, GSK3 promotes actin and tubulin
assembly (Koivisto et al. 2004), processes required for
synaptic reorganization during memory formation. We
propose, therefore, that GSK3 acts as a gate through which
LTP and memory are established. Considering, GSK3
activity is increased in AD, memory failure in this disorder
might be attributable to the inhibition of LTP with neuronal
loss ensuing as the disease progresses.
GSK3 and tau phosphorylation
Both GSK3b and GSK3a (Hanger et al. 1992; Ishiguro et al.
1992; Lovestone et al. 1994; Cho and Johnson 2003; Asuni
et al. 2006) induce the hyper-phosphorylation of tau at both
primed and non-primed phosphorylation sites, in vitro and in
Fig. 1 GSK3 and its role in AD. Over-
activity of GSK3 caused either by aberrant
Wnt or insulin signaling in sporadic AD
cases or through familial mutations in PS or
APP in FAD, might play an integral role in
disease progression. GSK3 mediates the
hyper-phosphorylation of tau, the increased
production of Ab from APP (via b and c
secretase-mediated cleavage) and results
in impairments in learning and memory and
could potentially heighten microglial-medi-
ated inﬂammatory responses in the local
vicinity of Ab plaques.
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as an important tau-kinase possibly involved in the formation
of NFTs in vivo. Consistent with this, GSK3b transgenic
mice display tau hyper-phosphorylation and neurodegener-
ation (Lucas et al. 2001) and chronic lithium (GSK3
inhibitor) treatment prevents tau hyper-phosphorylation and
NFT formation in double transgenic mice over-expressing
GSK3b and tau (harboring a triple mutation associated with
frontotemporal dementia and parkinsonism linked to chro-
mosome 17), although reversal of pre-formed tangles was not
observed (Engel et al. 2006). Similarly, double-transgenic
Drosophila over-expressing tau and shaggy, the Drosophila
form of GSK3, exhibit neuronal impairment and tau
pathology (Mudher et al. 2004).
Insulin transiently increases tau phosphorylation in human
neuroblastoma cells, but this is soon followed by a reduction
in tau phosphorylation, which correlates with the activation
and subsequent inhibition of GSK3 (Lesort et al. 1999).
Dickkopf, a negative regulator of Wnt signaling also
promotes tau phosphorylation and neurodegeneration
through the activation of GSK3 (Caricasole et al. 2004)
and Dickkopf is up-regulated in AD. Furthermore, PS-1
binds both GSK3b and tau, and mutant forms of PS-1,
associated with FAD, bind GSK3b more effectively resulting
in increased tau phosphorylation (Takashima et al. 1998).
PS-1 has been shown to inactivate GSK3 through PI3-kinase/
Akt signaling preventing tau phosphorylation and apoptosis.
Interestingly, PS-1 FAD mutations inhibit PS-1-dependent
PI3-kinase/Akt signaling, facilitating GSK3 activity and thus
tau hyper-phosphorylation. This is one potential mechanism
through which FAD mutations might lead to accelerated
disease progression through secondary aberrations in GSK3
activity (Baki et al. 2004).
GSK3 and Ab production
GSK3a, but not GSK3b, has been shown to regulate APP
cleavage resulting in the increased production of Ab (Sun
et al. 2002; Phiel et al. 2003). Exposure of neurones to Ab
increases GSK3b activity through the inhibition of PI3-kinase
signalling and blockade of either GSK3b expression or
activity prevents Ab-induced neurodegeneration (Takashima
et al. 1993, 1996; Alvarez et al. 1999). Although heightened
GSK3 activity is not the primary cause of disease in this
scenario, increased GSK3 activity would serve to augment
Ab production and in turn tau hyper-phosphorylation and
neuronal degeneration in both FAD and sporadic cases, in line
with the amyloid cascade hypothesis of AD.
Insulin signaling, possibly acting though the suppression
of GSK3 activity, has also been shown to exert a beneﬁcial
effect on APP and amyloid processing. Insulin increases the
expression of the Ab-protease, insulin degrading enzyme
(IDE) (Zhao et al. 2004) and enhances the secretion of
sAPPa, which results from the non-amyloidogenic a-secre-
tase-mediated cleavage of APP (Solano et al. 2000). We also
note with great interest the ﬁnding that in people with AD,
insulin given through the intranasal route favorably alters the
Ab40/42 ratio and improves cognition (Reger et al. 2007).
GSK3 and inﬂammation
As well as being implicated in the core pathogenic events of
AD – the increased formation of Ab, tau hyper-phosphor-
ylation and memory impairment – GSK3 might also play a
role in other processes thought to impact on the amyloid
cascade. Foremost amongst these are inﬂammatory pro-
cesses. There is a growing body of evidence to suggest that
inﬂammation plays an important role in AD. Microglia are
known to accumulate around Ab plaques in AD (Christie
et al. 1996; Joshi and Crutcher 1998; Stalder et al. 1999) and
there is increased expression of inﬂammatory mediators in
AD brain tissue (McGeer and McGeer 1996). Moreover,
Fc-dependent engagement of microglia is thought to be one
mechanism through which Ab immunotherapy operates. This
treatment strategy has proven successful in improving
cognitive function and reducing Ab plaque burden in both
animal models of AD and in human AD patients. However,
phase II clinical trials were aborted as some patients
developed symptoms of brain inﬂammation resembling
encephalitis or meningitis following injection with Ab
(Robinson et al. 2003; Schenk et al. 2005). In the periphery,
the regulation of GSK3 activity is critical for inﬂammatory
cell differentiation, inﬂammatory cell migration and the
secretion of pro-inﬂammatory cytokines (Woodgett and
Ohashi 2005; Jope et al. 2007; Rodionova et al. 2007).
However, little is known about the function of GSK3 in the
cerebral inﬂammatory response, which is predominantly
mediated by microglia. If, as we discuss above, GSK3
regulation is aberrant in AD brain, then this might impact
upon the cerebral inﬂammatory response leading to the
sustained secretion of neuro-toxic inﬂammatory mediators by
microglia, in turn causing by-stander damage to neighboring
neurons and contributing to neurodegenerative processes.
Concluding remarks
There is then substantial data strongly implicating GSK3 in
the pathogenesis of AD. GSK3 activity and/or protein levels
are increased in afﬂicted individuals with AD and cell
biological, epidemiological and genetic evidence points to an
association between AD and pathways that regulate GSK3.
We postulate these pathways augment GSK3 activity through
secondary changes in both regulatory Ser and Tyr phosphor-
ylation, mediated either directly or through alterations in the
insulin and/or Wnt signaling cascades or indeed through
other pathways that converge on GSK3.
In various cell culture, invertebrate and mammalian
models of AD increasing GSK3 activity leads to the hyper-
phosphorylation of tau, increased Ab generation and deﬁcits
in learning and memory accompanied with neurodegenera-
tion. Most importantly inhibiting GSK3 activity reverses
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mutated APP and tau in the best available models of AD
(Noble et al. 2005; Rockenstein et al. 2007). Our ‘GSK3
hypothesis of AD’ integrates and extends the well established
‘amyloid cascade hypothesis of AD’ incorporating the
known key molecular events and linking these with
outcomes such as memory impairment and inﬂammation. If
correct, then this hypothesis strongly implicates GSK3
inhibitors as a novel treatment strategy for AD.
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